The Clinical Trial Notification (CTN) and Clinical Trial Approval (CTA) schemes allow access to 'unapproved' therapeutic goods in clinical trials conducted in Australia.

This tool helps Australian trial sponsors determine whether the CTN or the CTA scheme is most appropriate for their clinical trial.

Other pathways are available to access 'unapproved' therapeutic goods for individual patients. Please note that health professionals should not use these pathways for the purposes of conducting a clinical trial.

See our guidance on Accessing unapproved products for more information about gaining access to 'unapproved' products.

Use this decision tool in conjunction with our information on Clinical trials and the Australian clinical trial handbook.